We are studying the safety and early effectiveness of AUTO1 in children with relapsed or refractory B cell acute lymphoblastic leukemia and aggressive mature B cell non-Hodgkin lymphoma. This trial aims to see how well the treatment works and how it can be safely administered.
Health conditions and diseases that the clinical trial is designed to study and treat.
B-cell Acute Lymphoblastic Leukemia (B-ALL) is a type of cancer that affects the blood and bone marrow, characterized by the rapid growth of immature B-cell lymphocytes, leading to symptoms like fatigue, fever, and easy bruising.
Aggressive Mature B-cell Non-Hodgkin Lymphoma (B-NHL) is a type of cancer that originates in the lymphatic system, leading to rapid growth of B-cell lymphocytes and symptoms such as swollen lymph nodes, fever, and weight loss.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.